Drug Repurposing Research Shows Promise for Alzheimer's

A comprehensive review published in Ageing Research Reviews reveals promising opportunities for treating Alzheimer's disease through drug repurposing—using existing medications with known safety profiles to address the complex pathophysiology of this devastating neurodegenerative condition. With over 55 million people affected globally and projections reaching 139 million cases by 2050, researchers are urgently seeking alternatives to current treatments that only manage symptoms.

What This Study Found

The research by More and colleagues examined the potential for repurposing existing medications to target multiple pathological pathways involved in Alzheimer's disease. The study suggests that this approach could accelerate therapeutic development by leveraging drugs with established safety profiles.

Researchers identified several categories of promising repurposed candidates:

Antidiabetic Agents: The study highlights metformin and GLP-1 receptor agonists as particularly promising options. These medications, traditionally used for diabetes management, may offer neuroprotective benefits through their effects on cellular metabolism and insulin signaling pathways.

Cardiovascular Medications: Anti-hypertensive drugs like candesartan showed potential benefits, suggesting that medications targeting cardiovascular health may also support brain health through improved vascular function.

Anti-inflammatory Compounds: The research found that NSAIDs and pioglitazone could address the neuroinflammation component of Alzheimer's pathology, which contributes to disease progression.

Mitochondrial-Targeted Therapies: Perhaps most notably, the study suggests that mitochondrial dysfunction represents a significant early factor in Alzheimer's development. Researchers identified compounds like SS-31, Mdivi-1, MitoQ, DDQ, and SkQ1 as promising disease-modifying options that target cellular energy production at the mitochondrial level.

Clinical Significance

The study's findings address a critical gap in Alzheimer's treatment options. Current FDA-approved therapies, including cholinesterase inhibitors and NMDA receptor antagonists, only provide symptomatic relief without addressing underlying disease mechanisms. Recently approved anti-amyloid monoclonal antibodies have shown limited clinical efficacy while presenting significant safety concerns and cost barriers.

The researchers suggest that drug repurposing offers several advantages over traditional drug development approaches. First, repurposed medications have established safety profiles, potentially reducing the risk of adverse effects during clinical trials. Second, this approach could significantly accelerate the timeline for bringing new treatments to patients, as these drugs have already undergone extensive safety testing.

The multi-target approach highlighted in the study is particularly significant. Alzheimer's disease involves complex, interconnected pathological processes including amyloid plaque formation, tau protein dysfunction, synaptic breakdown, neuroinflammation, and oxidative stress. The research suggests that addressing multiple pathways simultaneously through repurposed drug combinations could be more effective than targeting single mechanisms.

Current Access and Compliance Context

Many of the medications identified in this research are currently available for their original indications, which presents both opportunities and considerations for patients and healthcare providers. Metformin, for example, is widely prescribed for type 2 diabetes and has an extensive safety record. However, the study emphasizes that using these medications specifically for Alzheimer's treatment would constitute off-label use and requires careful medical supervision.

The researchers note that artificial intelligence, multi-omics approaches, and precision medicine technologies are enhancing drug repurposing strategies. These tools can help identify which patients might benefit most from specific repurposed therapies, potentially improving outcomes while minimizing risks.

It's important to understand that while these findings are encouraging, most repurposed candidates still require clinical trials specifically for Alzheimer's disease to establish efficacy and appropriate dosing protocols. The study suggests that regulatory pathways for repurposed drugs may be streamlined compared to novel drug development, but proper clinical validation remains essential.

What Patients Should Know

Patients and families affected by Alzheimer's disease should understand that while this research offers hope, these repurposing strategies are still being investigated. The study suggests promise for various approaches, but researchers emphasize that clinical trials specifically for Alzheimer's treatment are needed to confirm safety and efficacy.

The research indicates that the future of Alzheimer's treatment may involve combination therapies targeting multiple disease pathways simultaneously. This approach could potentially offer better outcomes than current single-target treatments, but such combinations require careful medical oversight to manage potential drug interactions and side effects.

Patients currently taking any of the medications mentioned in this research for other conditions should not modify their treatment regimens without consulting their healthcare providers. The dosing and monitoring requirements for Alzheimer's treatment may differ significantly from those used for the original indications.

The study also highlights the importance of early intervention, particularly given the focus on mitochondrial dysfunction as an early factor in disease development. This suggests that identifying and addressing metabolic and cellular health issues before significant neurodegeneration occurs could be crucial for prevention and treatment strategies.

For patients interested in participating in clinical trials investigating repurposed drugs for Alzheimer's disease, discussing options with specialized healthcare providers can provide information about current research opportunities and eligibility requirements.

Conclusion

This comprehensive research review demonstrates the significant potential of drug repurposing strategies for addressing the urgent need for effective Alzheimer's treatments. The study suggests that leveraging existing medications with known safety profiles, particularly those targeting mitochondrial function and multiple disease pathways, could accelerate the development of meaningful therapeutic options. While current treatments remain limited to symptom management, these research findings offer hope for disease-modifying approaches that could improve outcomes for millions of patients worldwide.

If you're interested in learning more about emerging treatment options or participating in clinical research, consider consulting with a healthcare provider experienced in neurodegenerative diseases. Visit peptideassociation.org/find-a-doctor to connect with qualified specialists in your area.

Medical Disclaimer: This content is for educational purposes only and should not be considered medical advice. Always consult with qualified healthcare professionals before making any changes to your treatment regimen or health management approach.

Citation: More PS, Rangari SW, Lade SN, et al. Drug repurposing in Alzheimer's disease: Emerging therapeutic strategies and promising candidates. Ageing Research Reviews. 2026;103113. doi:10.1016/j.arr.2026.103113